Flow Traders U.S.’s ProShares UltraShort NASDAQ Biotechnology BIS Stock Holding History

Flow Traders U.S.’s Portfolio BIS Stock Details BIS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-13	Closed	-$3K	–	504
2016 Q3	$3K	Buy	+13	New	+$3.45K	﹤0.01%	370
2014 Q4	–	Sell	-2,220	Closed	-$1.07M	–	185
2014 Q3	$1.07M	Buy	2,220 +2,167	+4,089%	+$1.15M	0.13%	53
2014 Q2	$30K	Buy	+53	New	+$36.5K	0.01%	137

Other funds holding BIS

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return

Flow Traders U.S.'s BIS Position: Q4 2016 in Review

Flow Traders U.S. sold out of ProShares UltraShort NASDAQ Biotechnology (BIS) in Q4 2016, closing a stake of 13 shares — an estimated $3K sold.

Flow Traders U.S. first reported a position in BIS in Q2 2014 and held it in 3 quarters. The position peaked at $1.07M in Q3 2014. 13 funds tracked by Wall St. Rank hold BIS as of Q4 2016.

Flow Traders U.S. reported no remaining ProShares UltraShort NASDAQ Biotechnology position as of Q4 2016 after selling out during the quarter.
Flow Traders U.S. sold 13 ProShares UltraShort NASDAQ Biotechnology shares in Q4 2016, an estimated $3K.
Flow Traders U.S. first reported a position in ProShares UltraShort NASDAQ Biotechnology in Q2 2014 and held it in 3 quarters.
Flow Traders U.S.'s ProShares UltraShort NASDAQ Biotechnology position peaked at $1.07M in Q3 2014.
13 funds tracked by Wall St. Rank held ProShares UltraShort NASDAQ Biotechnology as of Q4 2016.

Based on Flow Traders U.S.'s 13F filing for Q4 2016, filed 14 Feb 2017.